Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 5/2014

01-05-2014 | Original Paper

No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case–control study

Authors: Fatima Zohra Moghtit, Meriem Samia Aberkane, Valérie Le Morvan, Lotfi Louhibi, Ricardo Bellot, Abdelkader Bousahba, Ahlem Megaiz, Mostefa Fodil, Sounnia Mediene-Benchekor, Faouzia Zemani-Fodil, Abdallah Boudjema, Jacques Robert, Nadhira Saidi-Mehtar

Published in: Medical Oncology | Issue 5/2014

Login to get access

Abstract

Colorectal cancer (CRC) is a complex and multifactorial disease, in which genetic and environmental factors both seem to play a part. Many epidemiological studies have explored the association between genetic polymorphisms of X-ray repair cross-complementing group 3 (XRCC3) (Thr241Met) and Xeroderma pigmentosum group D (XPD) lysine to glutamine at codon 751 (Lys751Gln) and risk of CRC in various populations; however, the results are controversial. We conducted this case–control study in a West Algerian population to assess the potential role of this genetic polymorphism on the risk of CRC in this population. Genomic DNA was extracted from blood samples collected from 129 sporadic CRC patients and 148 normal controls. The polymorphisms were determined by pyrosequencing technique. The distribution of XRCC3 Thr241Met and XPD Lys751Gln genotypes among controls did not differ significantly from those predicted by the Hardy–Weinberg distribution (p > 0.05). There were no significant differences in the genotypes distribution and allele frequencies between CRC patients and controls. A significant association was found between the combined heterozygous of XRCC3 and homozygous variant of XPD gene and CRC. This is the first study on DNA repair genetic polymorphisms in West Algerian population, and it suggests that the XRCC3 Thr241Met and XPD Lys751Gln polymorphisms may not be associated with the CRC risk in this population.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 Internet.Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://​globocan.​iarc.​fr, accessed on 22/07/2013.
2.
Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366–78.CrossRefPubMed
3.
Meddah D, Meddah B, Touil AT, Ghalek M, Sahraoui T. Étude épidémiologique du cancer du côlon chez des patients de l’Ouest algérien. J Afr du Cancer/Afr J Cancer. 2009;1(1):31–5.CrossRef
4.
Gertig DM, Hunter DJ. Genes and environment in the etiology of colorectal cancer. Semin Cancer Biol. 1998;8(4):285–98.CrossRefPubMed
5.
6.
de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, Sijmons RH, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomark Prev. 2002;11(11):1332–52.
7.
Wood RD, Mitchell M, Lindahl T. Human DNA repair genes. Mutat Res/Fundam Mol Mech Mutagen. 2005;577(1–2):275–83.CrossRef
8.
Hlavin EM, Smeaton MB, Noronha AM, Wilds CJ, Miller PS. Cross-link structure affects replication-independent DNA interstrand cross-link repair in mammalian cells. Biochemistry. 2010;49(18):3977–88.PubMedCentralCrossRefPubMed
9.
Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell. 1998;1(6):783–93.CrossRefPubMed
10.
Brenneman MA, Weiss AE, Nickoloff JA, Chen DJ. XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res/DNA Repair. 2000;459(2):89–97.CrossRef
11.
Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58(4):604–8.PubMed
12.
Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case–control study. Cancer Epidemiol Biomark Prev. 2005;14(11):2569–78.CrossRef
13.
Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 2000;60(20):5612–6.PubMed
14.
Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11(12):1399–407.CrossRefPubMed
15.
Improta G, Sgambato A, Bianchino G, Zupa A, Grieco V, La Torre G, et al. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case–control study in a Southern Italian population. Anticancer Res. 2008;28(5B):2941–6.PubMed
16.
Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma-pigmentosum group-D gene encodes a DNA helicase. Nature. 1993;365(6449):852–5.CrossRefPubMed
17.
Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 2001;15(1):15–23.CrossRefPubMed
18.
Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002;17(6):463–9.CrossRefPubMed
19.
Benhamou S, Sarasin A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol. 2005;161(1):1–14.CrossRefPubMed
20.
Jiang Z, Li C, Xu Y, Cai S, Wang X. Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010;123(1):203–12.CrossRefPubMed
21.
Skjelbred CF, Saebø M, Wallin H, Nexø BA, Hagen PC, Lothe IM, et al. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer. 2006;6(1):67.PubMedCentralCrossRefPubMed
22.
23.
Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):8.CrossRef
24.
Griffin CS. Aneuploidy, centrosome activity and chromosome instability in cells deficient in homologous recombination repair. Mutat Res/Fundam Mol Mech Mutagen. 2002;504(1–2):149–55.CrossRef
25.
Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis. 2001;22(9):1437–45.CrossRefPubMed
26.
Al-Hadyan KS, Al-Harbi NM, Al-Qahtani SS, Alsbeih GA. Involvement of single-nucleotide polymorphisms in predisposition to head and neck cancer in Saudi Arabia. Genet Test Mol Biomark. 2012;16(2):95–101.CrossRef
27.
López-Cima MF, González-Arriaga P, García-Castro L, Pascual T, Marrón MG, Puente XS, et al. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of Northern Spain. BMC Cancer. 2007;7:162.CrossRefPubMed
28.
Curtin K, Samowitz WS, Wolff RK, Ulrich CM, Caan BJ, Potter JD, et al. Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol Biomark Prev. 2009;18(12):3384–8.CrossRef
29.
Krupa R, Sliwinski T, Wisniewska-Jarosinska M, Chojnacki J, Wasylecka M, Dziki L, et al. Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer—a case control study. Mol Biol Rep. 2011;38(4):2849–54.PubMedCentralCrossRefPubMed
30.
Curwen GB, Murphy S, Tawn EJ, Winther JF, Boice JD Jr. A study of DNA damage recognition and repair gene polymorphisms in relation to cancer predisposition and G2 chromosomal radiosensitivity. Environ Mol Mutagen. 2011;52(1):72–6.PubMedCentralCrossRefPubMed
31.
Wang J, Zhao Y, Jiang J, Gajalakshmi V, Kuriki K, Nakamura S, et al. Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case–control study in an Indian population. J Cancer Res Clin Oncol. 2010;136(10):1517–25.CrossRefPubMed
32.
Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case–control study in Taiwan. BMC Cancer. 2005;5:12.PubMedCentralCrossRefPubMed
33.
Settheetham-Ishida W, Yuenyao P, Natphopsuk S, Settheetham D, Ishida T. Genetic risk of DNA repair gene polymorphisms (XRCC1 and XRCC3) for high risk human papillomavirus negative cervical cancer in Northeast Thailand. Asian Pac J Cancer Prev. 2011;12(4):963–6.PubMed
34.
Zhao Y, Deng X, Wang Z, Wang Q, Liu Y. Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Asian Pac J Cancer Prev. 2012;13(2):665–9.CrossRefPubMed
35.
Ben Salah G, Fendri-Kriaa N, Kamoun H, Kallabi F, Mekaouar-Rebai E, Fourati A et al. An interethnic variability and a functional prediction of DNA repair gene polymorphisms: the example of XRCC3 (p.Thr241 > Met) and XPD (p.Lys751 > Gln) in a healthy Tunisian population. Mol Biol Rep. 2012; 39(10):9639–9647.
36.
Mort R, Mo L, McEwan C, Melton DW. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer. 2003;89(2):333–7.PubMedCentralCrossRefPubMed
37.
Canbay E, Agachan B, Gulluoglu M, Isbir T, Balik E, Yamaner S, et al. Possible associations of APE1 polymorphism with susceptibility and HOGG1 polymorphism with prognosis in gastric cancer. Anticancer Res. 2010;30(4):1359–64.PubMed
38.
Benhamou S, Tuimala J, Bouchardy C, Dayer P, Sarasin A, Hirvonen A. DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer. 2004;112(5):901–4.CrossRefPubMed
39.
Wang Z, Zhang W. Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk. Tumor Biol. 2013;34(3):1421–9.CrossRef
40.
Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996;10(10):1219–32.CrossRefPubMed
41.
Coin F, Bergmann E, Tremeau-Bravard A, Egly JM. Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. EMBO J. 1999;18(5):1357–66.PubMedCentralCrossRefPubMed
42.
Moisan F, Laroche-clary A, Auzanneau C, Ricard N, Pourquier P, Robert J, et al. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis. 2012;33(5):962–8.CrossRefPubMed
43.
Moreno V, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, González S et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006; 12(7Pt1):2101–2108.
44.
Huang WY, Berndt SI, Kang D, Chatterjee N, Chanock SJ, Yeager M, et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidemiol Biomark Prev. 2006;15(2):306–11.CrossRef
45.
Joshi AD, Corral R, Siegmund KD, Haile RW, Marcha,d LL, Martinez ME et al. Red meat and poultry intake, polymorphisms in the nucleotide excision repair and mismatch repair pathways and colorectal cancer risk. Carcinogenesis. 2009; 30(3):472–479.
46.
Zhang Y, Ding D, Wang X, Zhu Z, Huang M, He X. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case–control studies. Int J Colorectal Dis. 2011;26(10):1257–64.CrossRefPubMed
47.
Bigler J, Ulrich CM, Kawashima T, Whitton J, Potter JD. DNA repair polymorphisms and risk of colorectal adenomatous or hyperplastic polyps. Cancer Epidemiol Biomark Prev. 2005;14(11):2501–8.CrossRef
48.
Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, et al. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011;12(3):433–42.CrossRefPubMed
49.
Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 2009;100(7):1261–6.CrossRefPubMed
50.
Le Morvan V, Smith D, Laurand A, Brouste V, Bellot R, Soubeyran I, et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with tratment outcome. Pharmacogenomics. 2007;8(12):1693–703.CrossRefPubMed
51.
Rezaei H, Motovali-bashi M, Khodadad K, Elahi A, Emami H, Naddaffnia H. Relationship between XPD Lys 751 Gln polymorphism and colorectal cancer risk: a case–control study in a population-based study. Gastroenterol Hepatol Bed Bench. 2013;6(1):18–24.
52.
Hansen RD, Sørensen M, Tjønneland A, Overvad K, Wallin H, Raaschou-Nielson O, et al. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res. 2007;619(1–2):68–80.CrossRefPubMed
53.
Jelonek K, Gdowicz-Kłosok A, Pietrowska M, Borkowska M, Korfanty J, Rzeszowska-Wolny J, et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51(3):343–52.CrossRefPubMed
54.
Engin AB, Karahalil B, Engin A, Karakaya AE. Oxidative stress, Helicobacter pylori, and OGG1 Ser326Cys, XPC Lys939Gln, and XPD Lys751Gln polymorphisms in a Turkish population with colorectal carcinoma. Genet Test Mol Biomark. 2010;14(4):559–64.CrossRef
55.
Ouyang FD, Yang FL, Chen HC, Asaduzzaman Khan M, Huang FM, Wan XX et al. Polymorphisms of DNA repair genes XPD, XRCC1, and OGG1, and lung adenocarcinoma susceptibility in Chinese population. Tumor Biology. 2013; 34(5):2834–2848.
56.
Park JY, Lee SY, Jeon HS, Park SH, Bae NC, Lee EB, et al. Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer. 2002;36(1):15–6.CrossRefPubMed
Metadata
Title
No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case–control study
Authors
Fatima Zohra Moghtit
Meriem Samia Aberkane
Valérie Le Morvan
Lotfi Louhibi
Ricardo Bellot
Abdelkader Bousahba
Ahlem Megaiz
Mostefa Fodil
Sounnia Mediene-Benchekor
Faouzia Zemani-Fodil
Abdallah Boudjema
Jacques Robert
Nadhira Saidi-Mehtar
Publication date
01-05-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0942-3

Other articles of this Issue 5/2014

Medical Oncology 5/2014 Go to the issue

Original Paper

Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma

Short Communication

Dose adjustment of carboplatin in patients on peritoneal dialysis

Original Paper

Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients

Original Paper

Genetic variations in MTHFR and esophageal squamous cell carcinoma susceptibility in Chinese Han population

Letter to the Editor

Very rare diseases in oncology

Original Paper

Relationship between concentrations of IGF-1 and IGFBP-3 and preoperative depression risk, and effect of psychological intervention on outcomes of high-grade glioma patients with preoperative depression in a 2-year prospective study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits